Published in Int J Gynecol Cancer on August 12, 2004
Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol (2011) 1.58
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol (2014) 0.98
Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev (2010) 0.97
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther (2013) 0.91
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology (2008) 0.89
Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health (2014) 0.86
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer (2014) 0.85
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma. Oncol Hematol Rev (2013) 0.82
The Globalization of Cooperative Groups. Semin Oncol (2015) 0.82
Endometrial cancer. Obstet Gynecol Clin North Am (2012) 0.79
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist (2016) 0.77
Use of aromatase inhibitors in practice of gynecology. J Ovarian Res (2015) 0.76
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep (2016) 0.75
TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways. Oncotarget (2016) 0.75
The Role of Steroid Sulfatase as a Prognostic Factor in Patients with Endometrial Cancer. Yonsei Med J (2016) 0.75
Chemoresistance and targeted therapies in ovarian and endometrial cancers. Oncotarget (2017) 0.75
Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus. Surg Pathol Clin (2012) 0.75
Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. Int J Gynecol Cancer (2017) 0.75
The Association of CYP19A1 Variation with Circulating Estradiol and Aromatase Inhibitor Outcome: Can CYP19A1 Variants Be Used to Predict Treatment Efficacy? Front Pharmacol (2017) 0.75
Long-term effects of nurse home visitation on children's criminal and antisocial behavior: 15-year follow-up of a randomized controlled trial. JAMA (1998) 7.13
Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst (1999) 6.51
Long-term effects of home visitation on maternal life course and child abuse and neglect. Fifteen-year follow-up of a randomized trial. JAMA (1997) 6.31
DNA recognition by GAL4: structure of a protein-DNA complex. Nature (1992) 5.60
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) (2002) 3.33
The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA (1993) 3.09
How different eukaryotic transcriptional activators can cooperate promiscuously. Nature (1990) 2.91
Spindle dynamics and the role of gamma-tubulin in early Caenorhabditis elegans embryos. Mol Biol Cell (2001) 2.87
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Preventing child abuse and neglect with a program of nurse home visitation: the limiting effects of domestic violence. JAMA (2000) 2.50
Polymerase II promoter activation: closed complex formation and ATP-driven start site opening. Science (1992) 2.42
Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol (1998) 2.36
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
The rational clinical examination. Does this patient have strep throat? JAMA (2000) 2.30
A general mechanism for transcriptional synergy by eukaryotic activators. Nature (1995) 2.29
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab (2000) 2.09
Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro. Mol Cell Biol (1989) 2.06
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol (2007) 2.03
Expression of enhanced levels of small RNA polymerase III transcripts encoded by the B2 repeats in simian virus 40-transformed mouse cells. Nature (1985) 1.98
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun (2001) 1.97
Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A (1979) 1.96
Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol (1999) 1.93
The acidic activator GAL4-AH can stimulate polymerase II transcription by promoting assembly of a closed complex requiring TFIID and TFIIA. Genes Dev (1992) 1.89
Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A (2001) 1.85
Recruitment of the putative transcription-repair coupling factor CSB/ERCC6 to RNA polymerase II elongation complexes. Mol Cell Biol (1997) 1.83
Syndrome and outbreak detection using chief-complaint data--experience of the Real-Time Outbreak and Disease Surveillance project. MMWR Morb Mortal Wkly Rep (2004) 1.78
Application of a new multinomial phase II stopping rule using response and early progression. J Clin Oncol (2001) 1.77
The effects of intracuff lidocaine on endotracheal-tube-induced emergence phenomena after general anesthesia. Anesth Analg (2000) 1.77
The requirement for the basal transcription factor IIE is determined by the helical stability of promoter DNA. EMBO J (1995) 1.77
Assembly of the isomerized TFIIA--TFIID--TATA ternary complex is necessary and sufficient for gene activation. Genes Dev (1996) 1.76
Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther (2006) 1.74
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Yeast HMG proteins NHP6A/B potentiate promoter-specific transcriptional activation in vivo and assembly of preinitiation complexes in vitro. Genes Dev (1996) 1.66
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer (2002) 1.62
Changes in the demographics and perioperative care of stage IA(2)/IB(1) cervical cancer over the past 16 years. Gynecol Oncol (2001) 1.61
Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol (1991) 1.60
Removing a barrier to computer-based outbreak and disease surveillance--the RODS Open Source Project. MMWR Morb Mortal Wkly Rep (2004) 1.60
Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. Clin Infect Dis (1999) 1.59
Fatty acid abnormality in adrenoleukodystrophy. J Neurochem (1976) 1.58
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet B Neuropsychiatr Genet (2007) 1.55
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Repair of a traumatically amputated penis with return of erectile function. J Urol (1991) 1.53
A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J (1992) 1.51
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol (2006) 1.51
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 1.48
Patient response to laryngeal mask insertion after induction of anaesthesia with propofol or thiopentone. Can J Anaesth (1993) 1.47
Mechanism for specificity by HMG-1 in enhanceosome assembly. Mol Cell Biol (2000) 1.44
DNA methyltransferase inhibitors-state of the art. Ann Oncol (2002) 1.43
Virus-specified protease in poliovirus-infected HeLa cells. Proc Natl Acad Sci U S A (1979) 1.42
Night-time intra-oesophageal bile and acid: a comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor. Aliment Pharmacol Ther (2011) 1.42
Reduction of severity of pruritus after elective caesarean section under spinal anaesthesia with subarachnoid morphine: a randomised comparison of prophylactic granisetron and ondansetron. Int J Obstet Anesth (2009) 1.41
Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series. Int J Gynecol Cancer (2007) 1.39
Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res (2001) 1.38
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. Leuk Res (1991) 1.38
Brucella abortus genes identified following constitutive growth and macrophage infection. Infect Immun (2001) 1.34
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther (2001) 1.33
The ZEBRA activation domain: modular organization and mechanism of action. Mol Cell Biol (1993) 1.33
Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem (1999) 1.32
A heteroduplex template circumvents the energetic requirement for ATP during activated transcription by RNA polymerase II. J Biol Chem (1994) 1.31
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res (2000) 1.30
Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol (2000) 1.30
How important is removal of the parametrium at surgery for carcinoma of the cervix? Gynecol Oncol (2002) 1.28
Arachnoid cyst and associated subdural hematoma. Observations on conventional roentgenographic and computerized tomographic diagnosis. Arch Neurol (1978) 1.27
Modulating the potency of an activator in a yeast in vitro transcription system. Mol Cell Biol (1994) 1.27
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol (2000) 1.26
The role of activators in assembly of RNA polymerase II transcription complexes. Curr Opin Genet Dev (1994) 1.25
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol (2005) 1.23
Risk factors for aboriginal low birthweight, intrauterine growth retardation and preterm birth in the Darwin Health Region. Aust N Z J Public Health (1997) 1.23
Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage (1993) 1.22
Mechanical properties of urogynecologic implant materials. Int Urogynecol J Pelvic Floor Dysfunct (2003) 1.20
Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials (2001) 1.20
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat (2010) 1.19
Changes in performance, muscle metabolites, enzymes and fibre types after short sprint training. Eur J Appl Physiol Occup Physiol (1998) 1.18
Cone-beam CT with megavoltage beams and an amorphous silicon electronic portal imaging device: potential for verification of radiotherapy of lung cancer. Med Phys (2002) 1.17
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol (2006) 1.17
Trisomy of the short arm of chromosome 17. Humangenetik (1974) 1.16
Correlation between exchange bias and pinned interfacial spins. Phys Rev Lett (2003) 1.16
Human leucocyte elastase and cathepsin G: structural and functional characteristics. Ciba Found Symp (1979) 1.13
Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health (2001) 1.13
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol (1994) 1.13
Intra-arterial thrombolysis of embolic proximal middle cerebral artery occlusion from presumed atrial myxoma. Neurology (1997) 1.13
Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat (1999) 1.12
Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer (2005) 1.09
Compensatory energetic relationships between upstream activators and the RNA polymerase II general transcription machinery. J Biol Chem (1998) 1.09
Mucolipidosis IV: novel mutation and diverse ultrastructural spectrum in the skin. Neuropediatrics (2002) 1.09
Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol (1997) 1.07
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood (2000) 1.07
Participation rates, weight loss, and blood pressure changes among obese women in a nutrition-exercise program. Public Health Rep (1990) 1.07